Irvine, Calif., March 10, 2010 — A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage, according to the UC Irvine neurologist who led the effort.
TUSCALOOSA, Ala., March 12, 2010 – Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms.
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Mar 12, 2010 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.
PARIS & BOSTON--(BUSINESS WIRE)--Ipsen (Paris:IPN) (Euronext: FR0010259150; IPN), a global biotechnology specialty care group, and Rhythm Pharmaceuticals (Rhythm), a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders
Stockholm, Sweden - March 12, 2009 - Swedish Orphan Biovitrum (STO: BVT) today announced an agreement with Amgen to run an additional Kineret® bulk drug campaign. In addition, Swedish Orphan Biovitrum will pay to buy-out previously agreed future sales milestones for Kineret and Kepivance.
TAIPEI, Taiwan, March 12 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability. Nemonoxacin is a novel non-fluorinated quinolone that has a broad spectrum of activity against gram-positive and gram-negative bacteria and atypical pathogens.
PARIS & BOSTON--(BUSINESS WIRE)--Mar 12, 2010 - Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals (Rhythm), a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen's proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 12, 2010 - Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute (NCI) investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Mar 12, 2010 - Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.
CLEVELAND--(BUSINESS WIRE)--Mar 12, 2010 - A collaborative project between Sanford-Burnham Medical Research Institute at Lake Nona and Analiza, Inc. has yielded aqueous solubility data for over 20,000 compounds in the NIH Molecular Library within the first 90 days of screening and characterization.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Mar 12, 2010 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to institutional and accredited investors.
ABBOTT PARK, Ill., March 11 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
Paris, France - March 11, 2010 - Sanofi-aventis announced today that it has completed its acquisition of 100% of Chattem, Inc., which is now a wholly-owned subsidiary of the sanofi-aventis Group.
Berlin, March 11, 2010 – Bayer Schering Pharma AG, Germany, announced today that an orphan drug designation has been granted by the FDA for the ciprofloxacin dry powder inhaler (DPI) for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients.
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Mar 11, 2010 - BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).
WHITEHOUSE STATION, N.J., March 11, 2010 -- Merck & Co., Inc. today said that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT study has performed a pre-specified interim analysis of efficacy data and also reviewed safety data from the IMPROVE-IT trial and has approved continuing the study.
NEW YORK --(AP)--Pfizer Inc. said Thursday the cancer drug Sutent did not meet key goals in two late-stage studies focusing on advanced breast cancer.
|
